Stopped: Study never initiated due to COVID pandemic, staffing changes
In this observational pilot study urine samples will be collected from women receiving neoadjuvant chemotherapy with doxorubicin for triple negative breast cancer to determine whether: 1) exposures bisphenol and phthalate levels change over the course of neoadjuvant chemotherapy, and 2) levels differ between black women and those of other racial groups. The hypothesis is that bisphenol and phthalate levels will be similar to those of the general US female population at the time of diagnosis, however levels will increase during treatment due to exposure to plastics in the medical setting. The investigators also hypothesize that because of differences in personal care product use, black women may have higher urinary levels of bisphenols and phthalates prior to starting chemotherapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
urinary bisphenol and phthalate metabolite levels
Timeframe: baseline
urinary bisphenol and phthalate metabolite levels
Timeframe: post-neoadjuvant chemotherapy (either 16 or 20 weeks)
change from baseline urinary bisphenol and phthalate levels at end of neoadjuvant chemotherapy
Timeframe: baseline and post-neoadjuvant chemotherapy (16 or 20 weeks)